About this trial
Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms. MDSC are one of the most important immunosuppressive cells, that also harbour non immunologic functions, favouring cancer invasion. These non immunologic functions of MDSC in lung cancer will be better characterized. Indeed, cellular mechanisms will be analysed by in vitro studies, assessing the effect of immunosuppressive cells, provided by fresh tumor samples, on phenotype and functions of lung cancer cell lines. The aim of this study is to better characterize immunosuppressive landscape of NSCLC and mechanisms involved in their protumor functions.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
consecutive patients
lung carcinoma surgically treated by surgery only
Disqualifiers
patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)
patient with concomitant or previous cancer (in the 2 years)
Trial population
Patients with lung carcinoma surgically treated by surgery only
Trial design
Cohort
Prospective
Treatments tested in this trial
Tumor samples
Procedure/SurgeryTumor samples will be collected by the pathologist at the reception of the tumor removed during surgery
Treatment groups
Trial outcomes
Primary outcomes
Comparative analysis of the modifications of phenotype and functions of lung cancer cell lines when exposed to MDSC extracted from patient tumor tissue
Functional in vitro studies of the effect of MDSC extracted from resected NSCLC prospectively collected on phenotype and function of lung cancer cell lines
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: